Kyverna Therapeutics (KYTX) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
TRex Bio is the larger company by market cap ($385.1 million vs $384.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | KYTX | TRXB |
|---|---|---|
| Share price | $6.21 | $14.03 |
| Market cap | $384.05M | $385.06M |
| 1-day change | -2.82% | +0.21% |
| YTD return | -32.02% | — |
| 1-year return | -7.79% | — |
| EPS (TTM) | $-2.93 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-161.31M | — |
| 52-week high | $13.67 | $15.50 |
| 52-week low | $5.96 | $13.50 |
| Distance from 52-week high | -54.57% | -9.48% |
| Analyst consensus | none | — |
| Avg. price target upside | +389.53% | — |
| Average volume | 886.42K | 1.26M |
| Shares outstanding | 61.84M | 27.45M |
| Employees | 149 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
KYTX vs TRXB FAQ
Which is bigger, Kyverna Therapeutics or TRex Bio?
TRex Bio (TRXB) is larger, with a market capitalization of $385.06M compared with $384.05M for Kyverna Therapeutics (KYTX).
Are Kyverna Therapeutics and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.